{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:15:36Z","timestamp":1785402936273,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.purol.2021.12.008","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T21:33:00Z","timestamp":1644442380000},"page":"326-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Instauration du traitement adjuvant endov\u00e9sical par \u00e9pirubicine des tumeurs de vessie n\u2019infiltrant pas le muscle\u00a0: premier retour national d\u2019exp\u00e9rience du CC-AFU vessie"],"prefix":"10.1016","volume":"32","author":[{"given":"P.","family":"Rollin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Larr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"M\u00e9jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12S","key":"10.1016\/j.purol.2021.12.008_bib0055","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1166-7087(20)30751-X","article-title":"[French ccAFU guidelines\u00a0\u2013\u00a0update 2020\u20132022: bladder cancer]","volume":"30","author":"Roupr\u00eat","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2021.12.008_bib0060","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1016\/j.purol.2019.01.006","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de Canc\u00e9rologie de l\u2019AFU\u00a0\u2013\u00a0Actualisation 2018\u20132020\u00a0: tumeurs de la vessie","volume":"28","author":"Roupr\u00eat","year":"2018","journal-title":"Prog Urol"},{"issue":"2","key":"10.1016\/j.purol.2021.12.008_bib0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An Individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus calmette-guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2021.12.008_bib0070","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006885.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1\u00a0bladder cancer. Cochrane Urology Group, \u00e9diteur","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev [Internet]"},{"issue":"5","key":"10.1016\/j.purol.2021.12.008_bib0075","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","article-title":"Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer\u00a0\u2014\u00a0The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG)","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2021.12.008_bib0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.purol.2020.03.009","article-title":"Recommandations CCAFU sur la prise en charge des cancers de l\u2019appareil urog\u00e9nital en p\u00e9riode d\u2019\u00e9pid\u00e9mie au Coronavirus COVID-19","volume":"30","author":"M\u00e9jean","year":"2020","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2021.12.008_bib0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.purol.2015.12.002","article-title":"[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment]","volume":"26","author":"Neuzillet","year":"2016","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.purol.2021.12.008_bib0090","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","article-title":"Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.purol.2021.12.008_bib0095","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.purol.2012.05.002","article-title":"[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer]","volume":"22","author":"Roupr\u00eat","year":"2012","journal-title":"Prog Urol"},{"issue":"2","key":"10.1016\/j.purol.2021.12.008_bib0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.purol.2015.10.005","article-title":"[Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment]","volume":"26","author":"Lailler","year":"2016","journal-title":"Prog Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722000069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722000069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:35:36Z","timestamp":1761114936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708722000069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1166708722000069"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2021.12.008","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Instauration du traitement adjuvant endov\u00e9sical par \u00e9pirubicine des tumeurs de vessie n\u2019infiltrant pas le muscle\u00a0: premier retour national d\u2019exp\u00e9rience du CC-AFU vessie","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2021.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}